A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in ...

MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the ...

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the ...

The use of a nomogram derived from prostate-specific membrane antigen (PSMA) PET/CT findings successfully predicted long-term outcomes in patients with high-risk and very high-risk prostate cancer, ...

A molecular imaging tool developed by researchers at the University of California's two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

Figure 1. Time to castration-resistant prostate cancer (CRPC) by PSMA PET/CT bone lesion cohort at initial staging. Kaplan Meier curves showing time to CRPC by bone lesion cohort on PSMA PET/CT at ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...